Table of Contents
Volume 1 | Issue 2
Publication Date: September 2002
Abstract
No Access
Pay-Per View
Full Text
Add to Cart
Editorial | ||
 70 |
Editorial Oliver Sartor |
|
Meeting Highlights | ||
72-78 |
Highlights from: The 2002 American Urological Association Orlando; Florida, May 25-30, 2002 Lori Johnson, David Lee, Oliver Sartor, James A. Eastham |
|
Research in Brief | ||
79-80 |
The Endothelin-1 Antagonist, Atrasentan, Improves Time to Progression and Quality of Life in Hormone-Refractory Prostate Cancer Maxine Fisher, William K. Oh |
|
Comprehensive Reviews | ||
81-89 |
The Evolving Role of Estrogen Therapy in Prostate Cancer William K. Oh |
|
90-96 |
Prediction of Progression: Nomograms of Clinical Utility Michael W. Kattan, Peter T. Scardino |
|
Original Contributions | ||
97-104 |
Three-Dimensional Conformal Therapy Versus Standard Radiation Therapy in Localized Carcinoma of Prostate: An Update Carlos A. Perez, Jeff M. Michalski, David Mansur, Mary Ann Lockett |
|
105-114 |
Pilot Study of a Utilities-Based Treatment Decision Intervention for Prostate Cancer Patients Sara J. Knight, Derek P. Nathan, Amy K. Siston, Michael W. Kattan, Arthur S. Elstein, Kathleen M. Collela, Michael S. Wolf, Nicholas S. Slimack, Charles L. Bennett, Robert M. Golub |
|
115-117 |
High Gleason Scores and Lower Prostate-Specific Antigen Levels in a Single Institution Over the Past Decade Zinelabidine Abouelfadel, Gary J. Miller, L. Michael Glode, Bulent Akduman, Robert E. Donohue, Ann Nedrow, E. David Crawford |
|
Translational Medicine | ||
118-124 |
Uteroglobin: A Potential Novel Tumor Suppressor and Molecular Therapeutic for Prostate Cancer Steven R. Patierno, Michael J. Manyak, Patricia M. Fernandez, Angela Baker, Ashani T. Weeraratna, David S. Chou, Greg Szlyk, K. Shane Geib, Christopher Walsh, John Patteras |
|
Commentary | ||
125 |
Approaches to Inhibit Invasiveness and Metastasis in Prostate Cancer Edwin M. Posadas, William L. Dahut |
|
